Fluoxetine - Herantis Pharma

Drug Profile

Fluoxetine - Herantis Pharma

Alternative Names: HER-801

Latest Information Update: 06 Aug 2014

Price : $50

At a glance

  • Originator Hermo Pharma
  • Developer Herantis Pharma
  • Class Antidepressants; Eye disorder therapies; Propylamines; Small molecules
  • Mechanism of Action Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Eye disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 Aug 2014 No development reported - Phase-II for Amblyopia (in adults) in Finland and Estonia (PO)
  • 27 May 2013 Hermo Pharma completes a phase II trial in Amblyopia (in adults) in Estonia and Finland (EudraCT2010-023216-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top